WallStreetZenWallStreetZen

NASDAQ: GANX
Gain Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for GANX

Based on 3 analysts offering 12 month price targets for Gain Therapeutics Inc.
Min Forecast
$6.00+135.29%
Avg Forecast
$8.00+213.73%
Max Forecast
$9.00+252.94%

Should I buy or sell GANX stock?

Based on 3 analysts offering ratings for Gain Therapeutics Inc.
Strong Buy
Strong Buy
1 analysts 33.33%
Buy
2 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their GANX stock forecasts and price targets.

GANX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-31
lockedlocked$00.00+00.00%2024-04-23
lockedlocked$00.00+00.00%2024-03-27

1 of 1

Forecast return on equity

Is GANX forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
27.86%

Forecast return on assets

Is GANX forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

GANX revenue forecast

What is GANX's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$400.0k
Avg 2 year Forecast
$293.0k
Avg 3 year Forecast
$230.0k

GANX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GANX$2.55$8.00+213.73%Strong Buy
ALGS$0.59N/AN/A
KRON$0.79$4.13+422.15%Strong Buy
AADI$1.80$5.00+177.78%Strong Buy
MLEC$1.17$6.00+412.82%Strong Buy

Gain Therapeutics Stock Forecast FAQ

Is Gain Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: GANX) stock is to Strong Buy GANX stock.

Out of 3 analysts, 1 (33.33%) are recommending GANX as a Strong Buy, 2 (66.67%) are recommending GANX as a Buy, 0 (0%) are recommending GANX as a Hold, 0 (0%) are recommending GANX as a Sell, and 0 (0%) are recommending GANX as a Strong Sell.

If you're new to stock investing, here's how to buy Gain Therapeutics stock.

What is GANX's revenue growth forecast for 2024-2026?

(NASDAQ: GANX) Gain Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.

Gain Therapeutics's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast GANX's revenue for 2024 to be $7,220,792, with the lowest GANX revenue forecast at $1,805,198, and the highest GANX revenue forecast at $12,636,385. On average, 3 Wall Street analysts forecast GANX's revenue for 2025 to be $5,289,230, with the lowest GANX revenue forecast at $3,249,356, and the highest GANX revenue forecast at $7,220,792.

In 2026, GANX is forecast to generate $4,151,955 in revenue, with the lowest revenue forecast at $4,151,955 and the highest revenue forecast at $4,151,955.

What is GANX's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: GANX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is GANX's Price Target?

According to 3 Wall Street analysts that have issued a 1 year GANX price target, the average GANX price target is $8.00, with the highest GANX stock price forecast at $9.00 and the lowest GANX stock price forecast at $6.00.

On average, Wall Street analysts predict that Gain Therapeutics's share price could reach $8.00 by May 31, 2025. The average Gain Therapeutics stock price prediction forecasts a potential upside of 213.73% from the current GANX share price of $2.55.

What is GANX's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: GANX) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.